| Primary information |
|---|
| sequence ID | Seq_4942 |
| Peptide sequence | LMIDQNTKSPLFMGKVVNPTQK |
| CancerPDF_ID | CancerPDF_ID63, CancerPDF_ID8598, |
| PMID | 16896061,23667664 |
| Protein Name | Alpha-1-antitrypsin precursor,Alpha-1 antitrypsin |
| UniprotKB Entry Name | A1AT_HUMAN,A1AT_HUMAN |
| Fluid | Serum,Serum |
| M/Z | 830.51,2488.32 |
| Charge | 1,1 |
| Mass (in Da) | 2489.3,2491 |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,FT-ICR MS/MS + nano-HPLC |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,NA |
| CancerPDF_ID | CancerPDF_ID63, CancerPDF_ID8598, |
| p-Value | 1.00E-05,NA |
| Software | MASCOT,MASCOT |
| Length | 22,22 |
| Cancer Type | Metastatic thyroid carcinomas,"Breast cancer, Lung cancer, Rectal cancer" |
| Database | NCBI refseq Protein Database,NA |
| Modification | NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy" |
| Regulation | NA,NA |
| Validation | Independent validation,NA |
| Sensitivity | 95% on independent dataset,NA |
| Specificity | 95% on independent dataset,NA |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |